Case study describes potential breakthrough in treatment of aggressive type of prostate cancer
Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...
Targeted Oncology13d
Continued Investigation of T-DXd Shows Promise in Breast Cancer
Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.
Hosted on MSN2mon
Confirmed Antitumor Activity with T-DXd for HER2-Positive Metastatic CRC
The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC). Almost 40% of patients treated with the ...
oncnursingnews15d
ADCs May Change the Landscape of HER2-Mutant NSCLC
An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.
Targeted Oncology17h
The Targeted Pulse: A Review of Last Month’s FDA Prominent Actions and Key Data Updates Advancing Treatment Across Disease Types
Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research to be ...
TMCnet18d
Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced a poster presentation on HMBD-802, a novel ...